Lansoprazole Arrow Lab

Lansoprazole, the active ingredient in Lansoprazole Arrow Lab, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is used to manage acid‑related disorders such as gastro‑esophageal reflux disease and peptic ulcer disease in adult patients.

GNH USA supplies Lansoprazole Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Lansoprazole is a proton pump inhibitor that reduces gastric acid production, and it is indicated for several acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: facilitates ulcer healing and reduces recurrence risk. - Helicobacter pylori eradication regimens: used in combination therapy to increase eradication rates. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may improve with continued therapy. - Nausea: feeling of stomach upset, usually transient. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema): require immediate medical attention. - Clostridioides difficile infection: may cause severe colitis. - Hypomagnesemia: low magnesium levels with prolonged use. - Bone fractures: increased risk with long‑term therapy. - Interstitial nephritis: inflammation of kidney tissue. - Hepatic injury: rare liver function abnormalities.

Before prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal and hepatic function: adjust use in severe impairment. - Evaluate for history of hypersensitivity: avoid if allergic to PPIs. - Monitor long‑term therapy: assess need for continued treatment after 8‑12 weeks. - Check for concomitant use of drugs requiring gastric pH alteration: may affect absorption. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at room temperature: keep in original container, protect from moisture and light.

Lansoprazole can alter the pharmacokinetics of several medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - High‑dose methotrexate: increased toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: increased serum levels, risk of toxicity. - Diazepam: heightened sedation, monitor CNS effects.